ReviewNature reviews. Urology2020
Understanding genomics and the immune environment of penile cancer to improve therapy.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.Cancers · 2026Review
- Soluble immune checkpoint proteins as predictive biomarkers for lymph node metastases in penile cancer.Frontiers in immunology · 2026Article
- Expression profile of small nucleolar RNAs (snoRNAs) in penile cancer.Translational andrology and urology · 2025Article
- Treatment strategies in human papillomavirus-related advanced penile cancer.Nature reviews. Urology · 2025Review
- Molecular characterization of metastatic penile squamous cell carcinoma in developing countries and its impact on clinical outcomes: LACOG 2018 translational study.The oncologist · 2025Article
- The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.Frontiers in immunology · 2025Review
- Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.Military Medical Research · 2024Review
- LncRNA sequencing reveals an essential role for the lncRNA-mediated ceRNA network in penile squamous cell carcinoma.Genes and immunity · 2024Article
- The impact of the tumor microenvironment on the survival of penile cancer patients.Scientific reports · 2024Article
- Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage.Cancers · 2024Article
- Advances in molecular basis of response to immunotherapy for penile cancer: better screening of responders.Frontiers in oncology · 2024Review
- SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer.Human genomics · 2023Article
- Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.JAMA network open · 2023Article
- ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.JCO global oncology · 2023Article
- A comprehensive analysis of penile cancer in the region with the highest worldwide incidence reveals new insights into the disease.BMC cancer · 2022Article
- Penile cancer: Updates in systemic therapy.Asian journal of urology · 2022Review
- Updates in the use of radiotherapy in the management of primary and locally-advanced penile cancer.Asian journal of urology · 2022Review
- Immune-based therapies in penile cancer.Nature reviews. Urology · 2022Review
- Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of penile squamous cell carcinoma (PSCC) has increased in developed countries over the past decades owing to increased human papilloma virus (HPV) exposure. Despite successful surgical treatment of locoregional PSCC, effective treatment options for advanced disease are limited. The prognosis of patients with bulky nodal and metastatic PSCC is dismal and new management approaches are urgently needed. Genomic analyses have provided transformative knowledge on the genomic and molecular landscape and tumour microenvironment of PSCC. Around one-quarter of patients with metastatic PSCC have clinically actionable genomic alterations in mechanistic target of rapamycin, DNA repair and receptor tyrosine kinase pathways. These patients might benefit from combined and sequential targeted therapies. HPV vaccination might be another therapeutic option as PSCC is genetically similar to other HPV-driven cancers. In addition, 40-60% of PSCC tumours show strong PDL1 expression, and the frequency of mutational signatures suggestive of immunotherapy resistance is low, pointing to potential utility of immunotherapy for PSCC. Finally, identification of the composition of the penile microbiota and its biological role might lead to new cancer prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.